Artia Global Partners’s Cytokinetics CYTK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$6.02M Buy
70,700
+54,400
+334% +$3.91M 1.11% 19
2026
Q1
$1.07M Buy
+16,300
New +$1.04M 0.22% 42
2024
Q2
Sell
-89,525
Closed -$6.28M 50
2024
Q1
$6.28M Buy
89,525
+57,412
+179% +$4.44M 1.26% 13
2023
Q4
$2.68M Buy
+32,113
New +$1.16M 0.78% 15

Other funds holding CYTK

Artia Global Partners's CYTK Position: Q2 2026 in Review

Artia Global Partners increased its Cytokinetics (CYTK) stake by 334% in Q2 2026, buying an estimated $3.91M and bringing the position to 70,700 shares worth $6.02M. The position accounts for 1.11% of the portfolio, ranked #19.

Artia Global Partners first reported a position in CYTK in Q4 2023 and has held it in 4 quarters since. The position peaked at $6.28M in Q1 2024. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Artia Global Partners held 70,700 shares of Cytokinetics worth $6.02M as of Q2 2026.
  • Artia Global Partners bought 54,400 Cytokinetics shares in Q2 2026, an estimated $3.91M.
  • Cytokinetics made up 1.11% of Artia Global Partners's portfolio in Q2 2026, its #19 holding.
  • Artia Global Partners first reported a position in Cytokinetics in Q4 2023 and has held it in 4 quarters since.
  • Artia Global Partners's Cytokinetics position peaked at $6.28M in Q1 2024.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Artia Global Partners's 13F filing for Q2 2026, filed 14 Aug 2026.